Overcoming the Raw Material Hurdle: Plasmids for Viral Vector-Based Gene Therapies
Summary: In order to prevent delays bringing cell and gene therapies to market, companies should be pro-active to avoid potential hurdles including a shortage of critical raw materials such as plasmid DNA (pDNA). In this article, discover how Catalent Cell & Gene Therapy recognizes the challenges faced when obtaining these raw materials, and how our investments in pDNA manufacturing secure our integrated supply chain.